EntryPoint Capital LLC Acquires New Shares in Travere Therapeutics, Inc. (NASDAQ:TVTX)

EntryPoint Capital LLC acquired a new stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 20,600 shares of the company's stock, valued at approximately $359,000.

A number of other large investors have also recently made changes to their positions in TVTX. R Squared Ltd purchased a new stake in Travere Therapeutics during the 4th quarter valued at about $53,000. Quarry LP purchased a new stake in Travere Therapeutics in the third quarter valued at approximately $105,000. Victory Capital Management Inc. purchased a new stake in Travere Therapeutics in the fourth quarter valued at approximately $182,000. Baader Bank Aktiengesellschaft purchased a new position in Travere Therapeutics during the 4th quarter worth approximately $192,000. Finally, Entropy Technologies LP purchased a new position in Travere Therapeutics during the 4th quarter worth approximately $214,000.

Travere Therapeutics Price Performance

NASDAQ TVTX traded down $1.76 during mid-day trading on Monday, hitting $17.92. The stock had a trading volume of 2,577,321 shares, compared to its average volume of 1,481,836. The firm's 50 day moving average is $20.75 and its 200 day moving average is $18.57. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68. The stock has a market capitalization of $1.59 billion, a price-to-earnings ratio of -4.37 and a beta of 0.75. Travere Therapeutics, Inc. has a twelve month low of $5.12 and a twelve month high of $25.29.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last issued its earnings results on Thursday, February 20th. The company reported ($0.73) EPS for the quarter, missing analysts' consensus estimates of ($0.58) by ($0.15). The business had revenue of $74.79 million during the quarter, compared to analyst estimates of $72.38 million. Travere Therapeutics had a negative net margin of 137.90% and a negative return on equity of 1,636.87%. Equities research analysts forecast that Travere Therapeutics, Inc. will post -1.4 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

TVTX has been the topic of several recent research reports. Canaccord Genuity Group upped their price objective on shares of Travere Therapeutics from $22.00 to $45.00 and gave the company a "buy" rating in a report on Wednesday, February 12th. Citigroup increased their price target on Travere Therapeutics from $31.00 to $35.00 and gave the stock a "buy" rating in a research report on Monday, February 24th. HC Wainwright raised their target price on Travere Therapeutics from $18.00 to $22.00 and gave the stock a "buy" rating in a report on Wednesday, January 15th. Cantor Fitzgerald reissued an "overweight" rating on shares of Travere Therapeutics in a report on Friday, February 21st. Finally, JPMorgan Chase & Co. upped their price objective on Travere Therapeutics from $42.00 to $44.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $30.62.

Insider Buying and Selling at Travere Therapeutics

In other news, insider Peter Heerma sold 3,074 shares of the business's stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $25.00, for a total transaction of $76,850.00. Following the transaction, the insider now owns 127,634 shares of the company's stock, valued at approximately $3,190,850. The trade was a 2.35 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Sandra Calvin sold 54,244 shares of the company's stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $25.00, for a total transaction of $1,356,100.00. Following the completion of the sale, the chief accounting officer now directly owns 54,410 shares of the company's stock, valued at $1,360,250. This represents a 49.92 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 191,335 shares of company stock worth $4,194,712. Insiders own 3.75% of the company's stock.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.